Sharenet Sites 
Sharenet Sites
Complementary Medicines Regulations effects on Ascendis - Correction
ASCENDIS HEALTH LIMITED
(Incorporated in the Republic of South Africa)
(Registration number 2008/005856/06)
ISIN: ZAE000185005 JSE share code: ASC
(“Ascendis” or “the Company”)
COMPLEMENTARY MEDICINES (“CMS”) REGULATIONS EFFECTS ON
ASCENDIS - CORRECTION
In response to the Business Day article published on 10 June 2014, Ascendis
hereby releases this corrective announcement which serves to clarify the
statement pertaining to the portion of Ascendis’ turnover affected by the new
CMS regulations.
It should be duly noted that Ascendis’ Consumer Brands Division represents
approximately 40% of the Company’s [annualised] turnover with Solal
representing approximately 8% of Ascendis’ annualised turnover. Up to a
maximum of 20% of Solal's sales are potentially impacted by the CMS
regulations which therefore amounts to 1,6% of Ascendis' annualised turnover
being potentially impacted by the regulations and not the 9% as reported within
the article.
Ascendis continues to perform well with robust organic growth, as previously
reported within the interim results announcement released on 3 March 2014.
11 June 2014
Johannesburg
Sponsor
Investec Corporate Finance
Financial Advisor
Coast2Coast Investments
Date: 11/06/2014 04:30:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
